Strategic partnerships Blanver actively pursues collaborations with public laboratories and international partners as seen in recent deals with Adalvo and Biophytis, indicating a receptive market for co-developed oncology and infectious disease products. Opportunity: approach Blanver with co-development, licensing, or distribution proposals in HIV/AIDS, Hepatitis C, oncology, hematology, and rare diseases.

Oncology focus Recent and ongoing partnerships emphasize oncology product development and value-add oncology offerings, suggesting a priority area for business development. Opportunity: propose senior- or mid-stage oncology assets, biosimilars, or adjunct therapies that can leverage Blanver’s manufacturing and regulatory capabilities.

Manufacturing scale Blanver operates two industrial units in São Paulo and has a history as a major excipients manufacturer now focusing on high-quality active pharmaceutical ingredients and medicines. Opportunity: engage for contract manufacturing, fill-finish, or scale-up services for mid-market biologics or small-m molecule products destined for the Brazilian market or Latin America.

Therapeutic breadth Portfolio expansion into HIV/AIDS, Hepatitis C, osteoporosis, CNS diseases, oncology, hematology and rare diseases indicates a broad therapeutic scope and potential readiness for varied partnerships. Opportunity: target scope-aligned assets across these therapeutic areas for licensing deals, technology transfers, or joint ventures.

Global outreach Active collaboration with international partners and a presence in the Brazilian market position Blanver as a bridge between global innovators and Latin American commercialization. Opportunity: offer market access, regulatory navigation, and distribution arrangements tailored to Brazil and neighboring regions, including biosimilars and specialty generics.